cbm 4a has been researched along with Experimental Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bieblová, J; Bubeník, J; Indrová, M; Kuropka, P; Pajtasz-Piasecka, E; Reinis, M; Rossowska, J | 1 |
| Bieblová, J; Bubeník, J; Indrová, M; Jandlová, T; Jinoch, P; Mendoza, L; Mikysková, R; Pajtasz-Piasecka, E; Símová, J; Smahel, M; Vonka, V | 1 |
| Bieblová, J; Indrová, M; Jandlová, T; Pajtasz-Piasecka, E; Reinis, M; Vonka, V | 1 |
3 other study(ies) available for cbm 4a and Experimental Neoplasms
| Article | Year |
|---|---|
HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cytotoxicity Tests, Immunologic; Flow Cytometry; Genetic Therapy; Human papillomavirus 16; Humans; Ifosfamide; Immunoenzyme Techniques; Immunotherapy; Interleukin-12; Lymphocytes, Tumor-Infiltrating; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Papillomavirus Infections; Tumor Cells, Cultured | 2009 |
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Cancer Vaccines; Cell Transformation, Viral; Combined Modality Therapy; Drug Screening Assays, Antitumor; Genes, MHC Class I; Genes, ras; Granulocyte-Macrophage Colony-Stimulating Factor; Histocompatibility Antigens Class I; Ifosfamide; Immunotherapy; Injections, Subcutaneous; Interleukin-12; Interleukin-2; Mice; Neoplasm Metastasis; Neoplasms, Experimental; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Repressor Proteins; Vaccination | 2003 |
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Topics: Animals; Cancer Vaccines; Disease Models, Animal; Down-Regulation; Genes, MHC Class I; Genetic Therapy; HLA Antigens; Human papillomavirus 16; Humans; Ifosfamide; Immunotherapy; Interleukin-12; Male; Mice; Neoplasm, Residual; Neoplasms, Experimental; Tumor Cells, Cultured; Up-Regulation | 2006 |